Cara Therapeutics Inc at Jefferies Healthcare Conference Transcript
Hi, good afternoon, everybody. Welcome to the 2023 Jefferies healthcare conference here in New York. My name is Dennis Ding, mid-cap biotech analyst here at Jefferies. And I have the great pleasure of having the Cara Therapeutics team here with me for a fireside.
So before we really dive into some questions, maybe give a brief overview around the company, the progress you guys have made over the last 12 months and just so everybody's on the same page.
Sure. Good afternoon, Dennis, and thanks for the invitation to the conference. So Cara Therapeutics, I mean, our strategy is quite simple. We want to be the leader in chronic pruritus. And we've accomplished a lot as a company. We actually have an approved drug called KORSUVA injection that we're actively launching is launching in the US and in Europe.
We have a partner, CSL Vifor, who's in charge of the launch, both in the US and in Europe. And we're expecting an approval in Japan in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
